Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQ-AI Regulatory News (IQAI)

  • There is currently no data for IQAI

Re. Flowers Direct

5 Apr 2012 11:34

RNS Number : 9162A
Flying Brands Limited
05 April 2012
 



5 April 2012

Flying Brands Limited (the "Company")

 

Refinancing of Flowers Direct deferred consideration payments

 

The Board wishes to announce that Flying Flowers (Jersey) Limited ("FFJ"), a subsidiary of the Company, has refinanced the deferred consideration payments due to be paid under the Flowers Direct transaction.

 

FFJ acquired the business operating under the 'Flowers Direct' name (as announced on 24 May 2010) for a total consideration of £2.95 million, satisfied by the payment of £1.45 million in cash and the issue of interest-free, unsecured loan notes to Palatine Private Equity Fund LP, formerly known as Zeus Private Equity Fund LP (No. LP011716) ("Palatine"), Zeus Founder Partner LP (No. SL005896) and Palatine Private Equity Private Investors LP, formerly known as Zeus Private Equity Private Investors LP (No.LP011715) to the value of £1.5 million. FFJ has repaid £0.5 million of these loan notes and FFJ and Palatine have agreed to refinance the outstanding £1 million debt pursuant to a new facility agreement dated 4 April 2012 between FFJ, the Company (as guarantor of FFJ's obligations) and Palatine ("Facility"). The Facility is secured by a second ranking charge in favour of Palatine over the freehold of Retreat Farm and is repayable in full on the earlier of either (i) completion of the disposal of Gardening Direct; or (ii) 31 December 2012.

 

This agreement, together with the proposed sale of its Garden Bird Supplies, Garden Centre Online and Listen2 businesses announced on 30 March,will allow the Company time to evaluate strategic options for its remaining gardening business.

 

 

 

For further information, please contact:

 

Flying Brands Limited 01245 228 300

Stephen Cook, Chief Executive

Stuart Dootson, Finance Director

 

Smithfield Consultants 020 7360 4900

John Kiely

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBELFBLZFXBBX
Date   Source Headline
27th May 20257:00 amRNSChange of Name
22nd May 20252:23 pmRNSResult of AGM
2nd May 20257:29 amRNSApplication: FDA Breakthrough Therapy Designation
29th Apr 202510:49 amRNSNotice of AGM
25th Apr 20251:46 pmRNSPublication of Annual Report
11th Apr 20253:32 pmRNSPromising Preliminary Results of Phase 1 Study
18th Mar 202510:38 amRNSPlacing to raise £250,000
3rd Feb 20257:00 amRNSIB Expands Distribution with Blackford
22nd Jan 20257:00 amRNSOperations Update
10th Jan 20257:49 amRNSIB and Prism Secure First Installation
20th Nov 20247:00 amRNSImaging Biometrics Expands Distribution
19th Nov 202411:27 amRNSBoard Changes
5th Nov 20247:00 amRNSNew Patent Application and Trading Update
15th Oct 202410:28 amRNSHolding(s) in Company
14th Oct 202412:08 pmRNSHolding(s) in Company
14th Oct 202412:05 pmRNSPDMR dealing and TR1 announcement
11th Oct 202410:42 amRNSAcquisition of Interest by Braveheart
25th Jun 20249:59 amRNSIB Opens Expanded Access Program
14th Jun 20248:38 amRNSClinical Trial Updates
29th May 20243:08 pmRNSResult of AGM
23rd May 20247:00 amRNSMajor East Coast Health System Chooses IB Nimble
20th May 20247:10 amRNSSecond FDA Rare Pediatric Disease Designation
17th May 20247:00 amRNSIB Software Enhances Clinical Decision-Making
10th May 20248:15 amRNSRare Pediatric Disease Designation Granted to GaM
2nd May 202412:47 pmRNSIB Announces Expanded Access Program for GaM
29th Apr 20243:26 pmRNSPublication of Annual Report
5th Mar 20247:00 amRNSGrant of Options
1st Mar 20248:22 amRNSHolding(s) in Company
1st Mar 20248:20 amRNSHolding(s) in Company
26th Feb 20247:00 amRNSResult of Broker Option and Total Voting Rights
22nd Feb 20247:00 amRNSPlacing and Broker Option
9th Feb 202412:49 pmRNSFDA Application Update
2nd Feb 20248:39 amRNSIB awarded a $100,000 grant
22nd Jan 202410:05 amRNSHolding(s) in Company
15th Jan 20247:01 amRNSDirector Dealings and Conversion of CLNs
15th Jan 20247:00 amRNSHolding(s) in Company
10th Jan 20247:00 amRNSIB Launching an Expanded Access Program for GaM
19th Dec 20232:29 pmRNSImaging Biometrics granted FDA “Fast-Track”
5th Dec 202310:58 amRNSIQ-AI Announces Positive Interim Phase 1 Results
20th Nov 20231:42 pmRNSHolding(s) in Company
9th Nov 202311:38 amRNSDirector Dealing and Conversion of CLNs
8th Nov 202310:59 amRNSApplication for Pediatric Rare Disease Designation
6th Nov 20231:02 pmRNSHolding(s) in Company
18th Oct 20232:29 pmRNSUpdate Regarding Imaging Biometrics LLC
13th Oct 20238:55 amRNSIB Letter to Shareholders
9th Oct 20237:00 amRNSOrphan Drug Status to GaM and Total Voting Rights
3rd Oct 202311:30 amRNSHolding(s) in Company
19th Sep 20232:32 pmRNSIQ-AI shares cease trading on the OTCQB
8th Sep 20237:00 amRNSReduced Gadolinium Approach Validated'
18th Aug 202312:06 pmRNSUpdate on Collaboration Agreement with Mayo Clinic

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.